we care
«The Company of Decade - the Russian pharmaceutical products manufacturer»

Prescription Pharmaceuticals (RX)

The Company's Rx products are sold both in the commercial segment of the pharmaceutical market, through the FRP, and in the hospital segment of the market. The priorities for our work in each segment are defined depending on the work strategy for each product at the stage of promotion. For the majority of Rx products at the stage of promotion, the focus was on the commercial segment as the largest segment of the market with a 50% share of Rx products, in value terms. Given that the share of Rx products in the Company’s sales structure in 2011 was lower than the share of OTC sales (Rx 19.3%, OTC 78.6%), there is an obvious potential for increasing the Company’s Rx sales and the number of Rx products.

In 2011, Pharmstandard enjoyed great sales results in the segment of Rx products which have won trust of the inhabitants of Russia due to their outstanding quality. Revenue from sales of Rx products amounted to RUR 3,798.2 million and increased by RUR 504 million or 15.3% vs. RUR 3,294.2 million in 2010.

In 2011, Pharmstandard achieved excellent organic sales results for its Rx products which have won trust of the inhabitants of Russia owing to the their excellent quality and accessibility. Sales leaders in value terms were Phosphogliv® (RUR 924.6 million), Biosulin® (RUR 409.2 million), Combilipen® (RUR 404.9 million), Rastan® (355.9 million), Octolipen® (RUR 188.7 million), Picamilon® (RUR 169.2 million). The main drivers of growth were: Phosphogliv® (+RUR 225.8 million, or 32.3%), Combilipen® (+RUR 125.8 million, 45.1%), Octolipen® (+RUR 95.9 million, or 103.2%), Azitrox® (+ RUR 50.0 million, or 50.3%), Biosulin® (+RUR 48.0 million, 13.3%) and Artrozan® (+RUR 48.0 million, or 134.3%).

This table shows sales results of the Company's TOP-10 Rx products for 2011:


2011

2010

Volume 11/10

Sales 11/10

BRAND

Volume (mln packs)

Sales (mln RUR)

% of total sales

Volume (mln packs)

Sales (mln RUR)

% of total sales

Change

%

Change

%

1

Phosphogliv

2.487

925

24.3%

2.083

699

21.2%

0.404

19.4%

226

32.3%

2

Biosulin

0.794

409

10.8%

0.731

361

11.0%

0.064

8.7%

48

13.3%

3

Combilipen

4.020

405

10.7%

2.919

279

8.5%

1.101

37.7%

126

45.1%

4

Rastan

0.249

356

9.4%

0.336

439

13.3%

-0.086

-25.7%

-83

-19.0%

5

Octolipen

0.920

189

5.0%

0.482

93

2.8%

0.438

90.8%

96

103.2%

6

Picamilon

4.010

169

4.5%

3.959

155

4.7%

0.051

1.3%

14

9.2%

7

Azitrox

0.874

149

3.9%

0.631

99

3.0%

0.242

38.4%

50

50.3%

8

Cyclodol

2.470

113

3.0%

2.730

120

3.7%

-0.260

-9.5%

-7

-5.7%

9

Cocarboxylase Hydrochloride

2.180

98

2.6%

4.402

216

6.5%

-2.223

-50.5%

-117

-54.4%

10

Sulfocamphocainum

2.024

92

2.4%

2.620

103

3.1%

-0.596

-22.8%

-11

-11.1%

TOP 10 total

20.027

2,905

76.5%

20.893

2,565

77.9%

-0.866

-4.1%

341

13.3%

Other brands

33.576

893

23.5%

22.629

729

22.1%

10.947

48.4%

163

22.4%

TOTAL SALES

53.603

3,798

100.0%

43.522

3,294

100.0%

10.081

23.2%

504

15.3%

Products






Menu
Company profile Mission Strategy Achievments Corporate Governance Shareholder structure Social Policy Products    Over The Counter (OTC)    Prescription Pharmaceuticals (RX)    Vital and Essential Pharmaceuticals (VEP)    Third Parties Pharmaceuticals (TPP)    Research & Development Facilities Corporate film Reorganization Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
Corporate film
Markets information WAP version
Delayed according to exchanges regulations. RUSTOCKS.com
Company profile Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
© 2007–2013 All rights reserved.
Terms of use www.pharmstd.com